EGFR and non-small cell lung carcinoma: Notably, the results of a retrospective chart review in patients with advanced non-squamous NSCLC initiating therapy between 2011 and 2013, with follow-up until 2016, revealed EGFR mutation testing rates of more than 97% in Taiwan [23].